Comparative Pharmacology
Head-to-head clinical analysis: CIBINQO versus INREBIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIBINQO versus INREBIC.
CIBINQO vs INREBIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIBINQO (abrocitinib) is a Janus kinase (JAK) inhibitor. It selectively inhibits JAK1, which modulates cytokine signaling involved in inflammatory pathways, including interleukin (IL)-4, IL-13, IL-31, and interferon-gamma, reducing the inflammatory response in atopic dermatitis.
Fedratinib is a selective Janus kinase 2 (JAK2) inhibitor. It inhibits JAK2 and its mutant forms, including JAK2V617F, leading to reduced phosphorylation of signal transducer and activator of transcription (STAT) proteins and decreased proliferation of abnormal hematopoietic cells.
100 mg orally once daily, with or without food.
100 mg orally twice daily continuously until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours in healthy subjects, supporting twice-daily dosing. No significant accumulation after multiple doses.
Terminal elimination half-life approximately 14 hours; supports twice-daily dosing for steady-state attainment within 3 days
Primarily excreted via feces (69%) and urine (20%) after oral administration. Renal elimination accounts for <1% of unchanged drug. Biliary excretion is the major route for metabolites.
Fecal (77.6% as metabolites, 2.2% as unchanged drug); renal (8.5% as metabolites, <1% as unchanged drug)
Category C
Category C
JAK Inhibitor
JAK Inhibitor